Droplet digital PCR-based circulating microRNA detection serve as a promising diagnostic method for gastric cancer

Zhao, Gaoping; Jiang, Tao; Liu, Yanzhuo; Huai, Guoli; Lan, Chunbin; Li, Guiquan; Ge, Jia; Wang, Kang; Mo-hua, Yang

doi:10.1186/s12885-018-4601-5

Cited by 49 publications

(29 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Zhou et al clarified that a 6-miRNA signature had the potential to be used to diagnose patients with esophageal squamous cell carcinoma [ 15 ]. Moreover, Zhao et al clarified that a 4-miRNA signature could be used for the diagnosis of gastric cancer [ 16 ]. In our study, we focused on the diagnosis of STAD.…”

Section: Discussionmentioning

confidence: 99%

Use of a Four-miRNA Panel as a Biomarker for the Diagnosis of Stomach Adenocarcinoma

Chen

Peng

et al. 2020

Disease Markers

View full text Add to dashboard Cite

Background. MicroRNAs (miRNAs) have been applied to cancer diagnosis taking into account their role in tumorigenesis. The main purpose of our study was to confirm the possibility of using miRNAs as noninvasive biomarkers for stomach adenocarcinoma (STAD) diagnosis. Methods. A total of 246 participants (130 STAD patients and 116 healthy controls (HCs)) were enrolled in this 3-phase study. Five STAD pools and 3 HC pools (with 4 participants in each pool) were used for the screening of the 28 miRNAs using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The training phase (30 STAD patients vs. 24 HCs) and validation phase (80 STAD patients vs. 80 HCs) were used to further verify the identity of these miRNAs. Kaplan–Meier survival analysis and bioinformatics analysis were also used. Results. The expression levels of miR-125b-5p and miR-196a-5p were upregulated in STAD serum, compared with the HCs, while miR-1-3p and miR-149-5p showed the opposite result. A four-serum miRNA panel was constructed, and the area under the receiver operating characteristic curve (AUC) was found to be 0.892 (95% CI: 0.834 to 0.936, sensitivity = 86.25 % , specificity = 78.75 % ). Only miR-125b-5p expression showed a significant difference between STAD patients and NCs in the survival analysis. The neurotrophin signaling pathway was associated with 4 miRNAs identified in STAD patients. Conclusion. The four-serum miRNA panel has great potential to be used as a noninvasive biomarker for STAD diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of a Four-miRNA Panel as a Biomarker for the Diagnosis of Stomach Adenocarcinoma

Chen

Peng

et al. 2020

Disease Markers

View full text Add to dashboard Cite

show abstract

“…19,20 Specific miRNAs in blood or tissue samples could serve as novel biomarkers, and detection of these could contribute to cancer diagnosis and clinical outcome prediction. [21][22][23] In the current research, we analyzed the expression of miR-602 in ESCC tumors compared with that in the corresponding non-cancerous esophageal tissues. It is the first time to identify miR-602 expression in ESCC.…”

Section: Discussionmentioning

confidence: 99%

Epigenetically Upregulated MicroRNA-602 Is Involved in a Negative Feedback Loop with FOXK2 in Esophageal Squamous Cell Carcinoma

Liu

Wang

et al. 2019

Molecular Therapy

View full text Add to dashboard Cite

MicroRNA is an endogenous, small RNA controlling multiple target genes and playing roles in various tumorigenesis processes. In this study, our results revealed that miR-602 expression levels in tumor tissues and preoperative serum from esophageal squamous cell carcinoma (ESCC) patients were higher than those in non-tumorous tissues and healthy volunteers. miR-602 overexpression was closely related to lymph node metastasis and TNM stages and correlated short overall, and it acted as an independent prognostic marker of ESCC. The methylation status of the miR-602 gene indicated more frequent hypomethylation of the CpG sites located upstream of the miR-602 gene in the ESCC tissues than in the adjacent normal tissues, and the methylation status of miR-602 correlated inversely with its expression levels. Subsequently, miR-602 overexpression promoted ESCC proliferation and metastasis and regulated cell cycles in vitro and in vivo. Mechanistically, a dual-luciferase experiment validated that Fork head box (FOX)K2 (FOXK2) was a direct target of miR-602. More importantly, systemic delivery of formulated miR-602 antagomir could reduce tumor growth and increased FOXK2 protein expression in nude mice. This work provides novel insight into the molecular pathogenesis of ESCC.

show abstract

“…Furthermore, the present study examined the association between ex-miR-21 and ex-miR-92a levels and clinicopathological characteristics, and revealed that high ex-miR-21 expression was significantly associated with tumor stage. Zhao et al (34) reported a significant association between plasma miR-21 levels and tumor size, lymph node metastasis and progression of tumor stage. The present study failed to observe any association between ex-miR-92a expression and clinicopathological characteristics.…”

Section: Discussionmentioning

confidence: 99%

Plasma exosome‑encapsulated microRNA‑21 and microRNA‑92a are promising biomarkers for the prediction of peritoneal recurrence in patients with gastric cancer

et al. 2019

View full text Add to dashboard Cite

In patients with gastric cancer (GC), peritoneal recurrence is a common risk and associated with poor prognosis. A novel biomarker for the prediction of high-risk peritoneal recurrence in patients with GC is desirable. The present study investigated the effectiveness of exosome-encapsulated microRNAs (ex-miRNAs) as minimally invasive biomarkers in patients with GC that received curative surgery. Recurrence-specific ex-miRNAs were selected following comparison of miRNA microarray data from patients with TNM stage II GC with peritoneal recurrence (n=3) and without peritoneal recurrence following curative surgery (n=3), and three healthy volunteers. In this analysis, exosome-encapsulated miRNA-21 (ex-miR-21) and exosomal miR-92a (ex-miR-92a) exhibited the greatest alterations in expression patterns. Using plasma exosome samples collected from another 129 patients with stage II and III GC, the present study investigated the potential value of ex-miR-21 and ex-miR-92a as biomarkers. Ex-miRNA levels were measured using TaqMan miRNA assays. Ex-miR-21 levels were significantly higher and ex-miR-92a levels were significantly lower in samples from patients with GC compared with healthy controls. The overall survival (OS) and peritoneal recurrence-free survival (PRFS) were poorer in stage II and III patients with high ex-miR-21 levels than in patients with low miR-21 levels. OS and PRFS of stage II and III patients with low ex-miR92a levels were significantly worse than those with high ex-miR92a levels. Cox multivariate analyses indicated that ex-miR-21 and ex-miR-92a were independent prognostic factors for OS and PRFS in stage II and III GC. A negative correlation was detected between expression levels of miR-21 and programmed cell death protein 4 mRNA, and miR-92a and prostaglandin E receptor 4 mRNA. Therefore, ex-miR-21 and ex-miR-92a may function as effective and minimally invasive biomarkers for the prediction of peritoneal recurrence and the prognosis of patients with stage II/III GC.

show abstract

Droplet digital PCR-based circulating microRNA detection serve as a promising diagnostic method for gastric cancer

Cited by 49 publications

References 44 publications

Use of a Four-miRNA Panel as a Biomarker for the Diagnosis of Stomach Adenocarcinoma

Use of a Four-miRNA Panel as a Biomarker for the Diagnosis of Stomach Adenocarcinoma

Epigenetically Upregulated MicroRNA-602 Is Involved in a Negative Feedback Loop with FOXK2 in Esophageal Squamous Cell Carcinoma

Plasma exosome‑encapsulated microRNA‑21 and microRNA‑92a are promising biomarkers for the prediction of peritoneal recurrence in patients with gastric cancer

Contact Info

Product

Resources

About